Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis

220Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

Abstract

The chemokine CXCL12 (SDF-1) and its cell surface receptor CXCR4 were first identified as regulators of lymphocyte trafficking to the bone marrow. Soon after, the CXCL12/CXCR4 axis was proposed to regulate the trafficking of breast cancer cells to sites of metastasis. More recently, it was established that CXCR4 plays a central role in cancer cell proliferation, invasion, and dissemination in the majority of malignant diseases. The stem cell concept of cancer has revolutionized the understanding of tumorigenesis and cancer treatment. A growing body of evidence indicates that a subset of cancer cells, referred to as cancer stem cells (CSCs), plays a critical role in tumor initiation, metastatic colonization, and resistance to therapy. Although the signals generated by the metastatic niche that regulate CSCs are not yet fully understood, accumulating evidence suggests a key role of the CXCL12/CXCR4 axis. In this review we focus on physiological functions of the CXCL12/CXCR4 signaling pathway and its role in cancer and CSCs, and we discuss the potential for targeting this pathway in cancer management. © 2013 Cojoc et al.

Cite

CITATION STYLE

APA

Cojoc, M., Peitzsch, C., Trautmann, F., Polishchuk, L., Telegeev, G. D., & Dubrovska, A. (2013). Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. OncoTargets and Therapy. https://doi.org/10.2147/OTT.S36109

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free